PROTARA THERAPEUTIC INC (TARA) Stock Price, Forecast & Analysis
USA - NASDAQ:TARA - US74365U1079 - Common Stock
TARA Key Statistics, Chart & Performance
The current stock price of TARA is 4.44 USD. In the past month the price decreased by -12.43%. In the past year, price increased by 74.8%.
TARA Latest News, Press Relases and Analysis
TARA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About TARA
Company Profile
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Company Info
PROTARA THERAPEUTIC INC
345 Park Avenue South, 3rd Floor
New York City NEW YORK 10010 US
CEO: Jesse Shefferman
Employees: 28
Phone: 16468440337
PROTARA THERAPEUTIC INC / TARA FAQ
What does TARA do?
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Can you provide the latest stock price for PROTARA THERAPEUTIC INC?
The current stock price of TARA is 4.44 USD. The price decreased by -4.31% in the last trading session.
Does TARA stock pay dividends?
TARA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TARA stock?
TARA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does PROTARA THERAPEUTIC INC have?
PROTARA THERAPEUTIC INC (TARA) currently has 28 employees.
What is PROTARA THERAPEUTIC INC worth?
PROTARA THERAPEUTIC INC (TARA) has a market capitalization of 171.30M USD. This makes TARA a Micro Cap stock.
What is the outstanding short interest for PROTARA THERAPEUTIC INC?
The outstanding short interest for PROTARA THERAPEUTIC INC (TARA) is 7.62% of its float.
TARA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TARA. When comparing the yearly performance of all stocks, TARA is one of the better performing stocks in the market, outperforming 93.84% of all stocks.
TARA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TARA. TARA has a great financial health rating, but its profitability evaluates not so good.
TARA Financial Highlights
Over the last trailing twelve months TARA reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS increased by 48.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.27% | ||
| ROE | -35.07% | ||
| Debt/Equity | 0 |
TARA Forecast & Estimates
12 analysts have analysed TARA and the average price target is 25.5 USD. This implies a price increase of 474.32% is expected in the next year compared to the current price of 4.44.